Cory M. Richman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Cory M. Richman has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra Rasnitsyn
The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Canada
11 shared publications - Ana Guerreiro Stucklin
Division of Oncology and Children’s Research Center, University Children’s Hospital of Zurich, Zurich, Switzerland
11 shared publications - Borja L. Holgado
The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Canada
11 shared publications - Celio Pouponnot
Institut Curie, Orsay, France
11 shared publications - Craig Daniels
13Texas Children’s Cancer and Hematology Center, Houston, Texas
11 shared publications - David R. Raleigh
Department of Radiation Oncology, University of California San Francisco , San Francisco, California
11 shared publications
Latest Publications
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
Supplementary Table 2 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
Supplementary Table 2 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
Supplementary Table 1 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
Supplementary Table 1 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
Supplementary Table 3 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
Supplementary Table 3 from Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy